Oral Steroids do not Increase Risk of COVID 19 in Patients of chronic rhinosinusitis

Written By :  MD Bureau
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-04-21 08:30 GMT   |   Update On 2021-04-21 08:30 GMT

The role of corticosteroids in treating severe infections has been an enduring controversy. During the coronavirus disease 2019 (COVID-19) pandemic, rigorous data on the efficacy of corticosteroids have been limited. The pandemic has been a potent stimulus for clinical research addressing this controversy. In a recent study, researchers found that in patients with chronic rhinosinusitis (CRS), oral corticosteroids (OCS) does not increase the risk of COVID 19 infection. The research has been published in the journal Otolaryngology-Head and Neck Surgery on April 13, 2021.

CRS management frequently comprises conservative treatment, including a combination of topical and OCS. However, in the midst of the COVID-19 pandemic, clinicians may have been reluctant to prescribe OCSs out of possible concern for an increased risk of contracting COVID-19 or developing more severe COVID-19 symptoms.

Therefore, Dr Lauren E. Miller and Dr Neil Bhattacharyya conducted a study to explore the association between the use of OCSs and the development of COVID-19 in patients with CRS.

It was a historical cohort study of 1707 patients with chronic rhinosinusitis. The researchers stratified the patient subset into two groups: those who received OCSs within 28 days before their COVID-19 testing and those who did not and recorded the number of days between the initial OCS prescription and the COVID-19 test.

Key findings of the study were:

Upon analysis, the researchers found no statistically significant difference in the rates of patients with a positive diagnosis of COVID-19 who underwent an OCS treatment regimen compared to those who did not, both within 28 days and 14 days prior to the COVID-19 test.

The authors concluded, "Given OCSs are often a major component of medical management of CRS, this study proves helpful in counseling patients on risks of steroid use in CRS treatment during the COVID-19 pandemic."

For further information:

DOI: https://doi.org/10.1177/01945998211006931


Tags:    
Article Source :  Otolaryngology-Head and Neck Surgery

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News